

# EUROPEAN PATENT OFFICE

## Patent Abstracts of Japan

PUBLICATION NUMBER : 11302280  
 PUBLICATION DATE : 02-11-99

APPLICATION DATE : 17-04-98  
 APPLICATION NUMBER : 10106841

APPLICANT : ONO PHARMACEUT CO LTD;

INVENTOR : NAKADE SHINJI;




INT.CL. : C07D417/06 C07D417/06 A61K 31/425  
 A61K 31/425 A61K 31/425 A61K  
 31/425 A61K 31/425 A61K 31/425  
 A61K 31/425 A61K 31/425

TITLE : THIAZOLIDINE DERIVATIVE, AND  
 MEDICINE CONTAINING THE SAME  
 AS ACTIVE INGREDIENT

ABSTRACT : PROBLEM TO BE SOLVED: To obtain the subject medicine having sialyl Lewis X synthesis inhibiting effect by including a specific thiazolidine derivative as the active ingredient, and hence useful for treatment of various diseases, e.g. inflammatory diseases, chronic rheumatoid arthritis, allergy, glomerulonephritis, hepatitis, disseminated sclerosis, colitis ulcerosa, autoimmune disease and cancer.

SOLUTION: This medicine contains, as the effective ingredient, a compound shown by formula I (A<sup>1A</sup>, A<sup>2A</sup> and A<sup>3A</sup> are each O or S; R<sup>1A</sup> is a 1-4C alkyl, hydroxyl group or the like; R<sup>2A</sup> is H, a 1-4C alkyl or the like; mA is 1 to 3; Cycle A is a carbon ring or hetero ring; solid and broken double lines are each single or double bond), or a salt or hydrate thereof. Of the compounds shown by formula I, 3-amino-5-(5-(4-chlorophenyl)furan-2-ylmethylene)-2-thioxo-4-thiazoline and the like are new ones. These new compounds are obtained by reacting a compound shown by formula II (A<sup>1B</sup> is A<sup>1A</sup>; R<sup>2B</sup> is R<sup>2A</sup>; mB is mA; and Cycle B is cycle A) with a compound shown by formula III (A<sup>2B</sup> and A<sup>3B</sup> are each A<sup>1A</sup>; and R<sup>1B</sup> is R<sup>1A</sup>).

COPYRIGHT: (C)1999,JPO



I

II

III